Tissue plasminogen activator‐mediated PDGF signaling and neurovascular coupling in stroke

The use of tissue plasminogen activator (tPA) as a thrombolytic treatment in ischemic stroke is limited largely due to concerns for hemorrhagic complications. The underlying mechanisms are still unknown, but evidence is beginning to emerge that tPA interacts with key regulators of the neurovascular...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and haemostasis 2009-07, Vol.7 (Suppl 1), p.155-158
Main Authors: SU, E. J., FREDRIKSSON, L., SCHIELKE, G.P., ERIKSSON, U., LAWRENCE, D.A.
Format: Article
Language:English
Subjects:
Blood Vessels - innervation
blood–brain barrier
Cerebrovascular Circulation
Humans
LRP
Medicin och hälsovetenskap
neurovascular unit
PDGF
Platelet-Derived Growth Factor - metabolism
Signal Transduction
stroke
Stroke - drug therapy
Tissue Plasminogen Activator - pharmacology
Tissue Plasminogen Activator - therapeutic use
tPA
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of tissue plasminogen activator (tPA) as a thrombolytic treatment in ischemic stroke is limited largely due to concerns for hemorrhagic complications. The underlying mechanisms are still unknown, but evidence is beginning to emerge that tPA interacts with key regulators of the neurovascular unit (NVU), and that these interactions may contribute to the undesirable side effects associated with the use of tPA in ischemic stroke. Understanding these connections and tPA’s normal function within the NVU may offer new insights into future therapeutic approaches.
ISSN:1538-7933
1538-7836
1538-7836
DOI:10.1111/j.1538-7836.2009.03402.x